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Summary
Every year, Candida, Aspergillus, Cryptococcus and
Pneumocystis infect an estimated two million individuals
worldwide. Most are immunocompromised or critically ill.
Candida is the most common fungal pathogen of the crit-
ically ill and of recipients of transplanted abdominal or-
gans. In high-risk haemato-oncological patients, in con-
trast, the introduction of antifungal prophylaxis with fluc-
onazole and later with mould-active posaconazole has led
to a remarkable reduction of invasive candidiasis and is
likely to have a similar effect on invasive aspergillosis. In-
vasive aspergillosis remains the dominant invasive fungal
disease (IFD) of haemato-oncological patients and solid-
organ transplant recipients and is increasingly found in in-
dividuals with exacerbated chronic obstructive pulmonary
disease on corticosteroids. In the developed world, ow-
ing to antiretroviral therapy Pneumocystis pneumonia and
cryptococcosis have become rare in patients with human
immunodeficiency virus (HIV) and are mainly found in
solid-organ transplant recipients or immunocompromised
patients. In the developing world, cryptococcosis remains
a common and highly lethal disease of HIV positive indi-
viduals.
With invasive candidiasis and invasive aspergillosis, timely
diagnosis is the principal challenge. The clinical presenta-
tion is nonspecific and current diagnostic tests lack sens-
itivity and specificity. The combination of several tests
improves sensitivity, but not specificity. Standardised poly-
merase chain-reaction-based assays may be promising
tools for more rapid and specific diagnosis of candidiasis
and invasive aspergillosis. Nevertheless, initiation of treat-
ment is often based solely on clinical suspicion. Empirical
therapy, however, may lead to over-treatment of patients
without IFD or it may miss its target in the case of resist-
ance. Despite the success of antifungal prophylaxis in re-
ducing the incidence of IFDs in haemato-oncological pa-
tients, there are a considerable number of breakthrough
infections demonstrating not only fungal resistance but also
the emergence of rare and often lethal fungal pathogens.
Knowledge of the local epidemiology and antifungal res-
istance is therefore pivotal. Current trial-based guidelines
leave major gaps in identifying those most at risk, who may
benefit from prophylaxis. Ongoing searches for disease-
associated genetic polymorphisms may contribute to the
establishment of individual risk profiles and targeted pro-
phylaxis.
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Introduction
Out of more than 100'000 known fungal species, only about
300 cause disease in humans [1]. Our body temperature
may provide a protective thermal barrier against the ma-
jority of species that grow best at ambient temperature [2].
The most common pathogens are Candida, Aspergillus,
Cryptococcus, and Pneumocystis spp. – causing more than
90% of reported deaths due to fungal disease [3]. The top
ten fungal infections are responsible for at least as many
deaths as tuberculosis or malaria [3–5]. Yet, on a global
scale, fungal diseases are neglected. This is reflected by the
lack of initiatives by the World Health Organization and the
paucity of national surveillance programmes [3]. Although
current trends show an overall increase of invasive fungal
diseases (IFDs), their incidence is likely to be underestim-
ated [6].
IFDs are associated with high morbidity and mortality.
Their diagnosis is challenging and their timely treatment
often depends on a high level of clinical suspicion. There-
fore, this review aims to give an overview of the current
epidemiology, clinical presentation, diagnosis, and man-
agement of the four most common IFDs: invasive candidi-
asis, aspergillosis, cryptococcosis, and Pneumocystis pneu-
monia.
Definitions of invasive fungal disease
IFDs are proven by the presence of moulds or yeasts in a
deep tissue biopsy or a culture obtained by a sterile pro-
cedure [7]. Additional definitions for probable and possible
IFDs based on host-specific, clinical, and mycological fea-
tures, which were originally established for haemato-onco-
logical research purposes, are now commonly applied in
the clinical setting [8]. However, these definitions lack pre-
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 12
cision and universal applicability to all patients groups –
notably the critically ill – and do not include Pneumocystis
pneumonia.
Invasive candidiasis
Candida is the most common cause of IFDs in the deve-
loped world [9]. As a normal commensal of humans, this
yeast may be found in the oral cavity, the gastrointestinal
tract, the female genital tract or on the skin [10]. An es-
timated 24–70% of healthy people above one year of age
are colonised by Candida. Presumably, everyone is tem-
porarily colonised at least once during their lifetime [11,
12]. Invasive candidiasis originates from the patient’s own
flora: it is introduced into the bloodstream or deep tissue
following iatrogenic breaks of the skin or mucosal barrier.
Since its introduction in the 1990s, antifungal prophylaxis
with fluconazole has led to a remarkable reduction of can-
didaemia in haemato-oncological patients [13–16]. Invas-
ive candidiasis is predominantly a disease of the critically
ill, hospitalised patient.
Epidemiology
The incidence rate of invasive candidiasis shows a large
geographical variation. In Europe, invasive candidiasis
makes up 2-3% of all nosocomial infections – four times
less than in the USA [9, 17–20]. Despite an increased use
of antifungals, the incidence of candidaemia is on the rise.
Between 2000 and 2010 its incidence rate in Swiss hos-
pitals has doubled from 0.49 to 1.01/10 000 patient days
[21]. A similar trend was observed in other European sur-
veillance studies, with an average incidence rate increasing
to approximately 0.59/10 000 population and 11/10 000 ad-
missions [22–25]. Incidence rates in intensive care unit
(ICU) patients are 5–10 times higher than in patients from
medical or surgical wards [20, 22, 26]. The average 30-day
mortality rate for candidaemia is 43% [27, 28]. This is sub-
stantially higher than for any other blood stream infection
[29].
The main risk factor and principal portal of entry for can-
didaemia is an intravenous (IV) catheter [30]. Candida
biofilms formed on IV catheters are also an important
source of continued infection [31]. Other critical risk
factors for candidaemia are the use of broad-spectrum anti-
biotics, total parenteral nutrition, dialysis, and chemother-
apy. Notably, all of these factors are associated with critical
illness [32–34]. In the USA TRANSNET study on solid-
organ transplant recipients, more than 50% of all fungal
infections were due to Candida with incidence rates in-
creasing from 1.4% to 2.1% between 2001 and 2006. In
particular, recipients of abdominal organs (liver, pancreas,
small bowel) were likely to become infected [35]. The prin-
cipal risk factors for invasive intra-abdominal candidiasis
are complicated abdominal surgery and pancreatitis, both
often leading to ICU admission. Its mortality rate in recent
studies was between 27–38% [36, 37].
Different Candida species
Worldwide, C. albicans remains the dominant Candida
species. Between 1991 and 2010, Funginos, the “Fungal in-
fection network of Switzerland”, reported a stable distri-
bution of blood-stream isolates of 65% C. albicans, 15%
C. glabrata, 6% C. tropicalis, 5% C. parapsilosis and 2%
C. krusei [21]. In contrast to the USA, in Switzerland and
Northern Europe no shift to fluconazole-resistant C. krusei
and C. glabrata has been observed [27, 38]. In some areas
(Southern Europe, the Americas and Asia) C. parapsilosis
is the second most common isolate after C. albicans. The
identification of Candida isolates to the species level is
important because of species-specific antifungal drug res-
istance patterns, which have major impact on the choice
of best treatment. More than 98% of C. albicans isolates
are susceptible to fluconazole [39], whereas C. krusei is
constitutiively resistant to fluconazole, but susceptible to
newer-generation azoles. Because of its wide array of res-
istance mechanisms, C. glabrata poses the greatest treat-
ment challenge [23, 27]: azole therapy is usually advised
against because of the capacity of C. glabrata to develop
or to extend resistance under treatment, and some studies
also report rapidly occurring and/or increased resistance to
echinocandins [40–42]. Previous azole exposure increases
the risk for infection with azole-resistant Candida isolates
[43–46].
Clinical presentation
Signs and symptoms of invasive candidiasis are nonspecif-
ic. Candidaemia is the most common manifestation, deep-
seated infections with or without concomitant candidaemia
are rarer. Intra-abdominal candidiasis may occur after com-
plicated abdominal surgery or with necrotising pancreatitis;
simultaneous candidaemia is detected in only 10% of cases
[47–49]. Candidaemia may go unnoticed when it produces
a single febrile peak among many – typically in the crit-
ically ill patient. It may induce sepsis or ultimately septic
shock, both indistinguishable from bacterial infection [43].
Signs of intra-abdominal candidiasis include persistent
fever and clinical deterioration despite continued antibiotic
treatment. Deep-seated organ infections are more common
in solid organ transplant recipients, whereas candidaemia
occurs more often in haematological or critically ill pa-
tients [50]. Candida pneumonia is rare [11, 51].
Candida chorioretinitis, found in approximately 8–16% of
candidaemic patients, may be an easily detectable sign of
recent or ongoing candidaemia. It is usually asymptomatic
unless progression to vitritis and vision-threatening en-
dophthalmitis produces blurred vision or floating black
spots [52, 53]. Progression beyond chorioretinitis is very
rare in patients treated for candidaemia but may occur up
to several months later if candidaemia was missed
Diagnosis
The diagnosis of candidaemia is often difficult. Because of
the lack of disease-specific signs and symptoms, clinical
suspicion drives diagnostic testing [56]. Despite their low
sensitivity of only 50–70%, blood cultures are still the gold
standard to diagnose candidaemia. Intermittent shedding of
organisms from deep-seated foci of infection, low patho-
gen counts per volume of blood or nonviable organisms re-
duce the sensitivity of modern blood culture methods [56].
Frequent sampling is recommended [57–59]. The diagnosis
of deep-seated candidiasis is based on positive cultures of
Review article: Current opinion Swiss Med Wkly. 2016;146:w14281
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 12
sterilely collected tissue samples, which are often difficult
to obtain [56].
Molecular tests such as the assay for (1–3)-β-D-glucan, a
cell wall component of various medically important fungi
(except Cryptococcus and mucormycetes), may detect can-
didaemia and intra-abdominal candidiasis. However, the
low sensitivity (65–75%) and specificity (80–85%) limit
the usefulness of the test, which is not commonly offered
by European microbiology laboratories [57, 60, 61].
A commercial, whole-blood, multiplex polymerase chain-
reaction (PCR) assay that detects the five clinically most
important Candida species, Aspergillus fumigatus as well
as several bacteria had a sensitivity of 94% in candidaemic
patients [62]. The T2 magnetic resonance assay, an auto-
mated, PCR-based method, appears to be a promising new
test for the rapid diagnosis of candidaemia [63]. MALDI-
TOF (matrix-assisted laser desorption/ionisation time of
flight) has been shown to accelerate correct identification
of Candida species [64]. To search for endophthalmitis,
a dilated fundoscopy is recommended for all candidaemic
patients with any visual symptom or those unable to report
symptoms (i.e. sedated patients) [52].
The detection of Candida in a respiratory or urinary sample
is almost always due to colonisation [11, 65]. Symptomatic
candiduria in a neutropenic patient, however, may indicate
a Candida cystitis that merits therapy. Persistence of can-
diduria after catheter removal may be due to colonised
foreign bodies in the urinary tract (i.e. kidney or bladder
stones) and requires imaging studies.
Treatment
Indications and agents for antifungal prophylaxis are listed
in table 1. Antifungal therapy (table 2) is indicated in all
patients with evidence of Candida in their blood culture re-
gardless of the presence of clinical symptoms [66]. As a
result of the nonspecific clinical presentation as well as the
poor sensitivity of diagnostic tests, treatment is mostly ini-
tiated on the basis of clinical suspicion. Following the latest
European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) guidelines all non-neutropenic can-
didaemia patients – regardless of the underlying disease –
should primarily receive an echinocandin or alternatively
liposomal amphotericin B [66–68]. For neutropenic pa-
tients (mostly after haematopoietic stem cell transplanta-
tion [HSCT]) echinocandins and amphotericin B are both
first choice [69]. For susceptible organisms, fluconazole
may be a reasonable choice for continuation therapy in
clinically improved patients. For all non-albicans Candida
spp. treatment is adapted in accordance with resistance test-
ing. They should initially be treated either with an echin-
ocandin or amphotericin B [66].
Treatment for candidaemia should be continued for 14 days
after the first negative blood culture [70]. All patients with
candidaemia should have daily blood cultures until clear-
ance of the blood stream infection is documented. In a
suspected catheter-associated infection, the invasive device
should be removed as soon as possible [66, 69]. The 2016
update of the Infectious Diseases Society of America
(IDSA) guideline includes suggested treatment durations
for some deep-seated infections [71].Combination therapy
is generally not recommended. Chorioretinitis is usually
sufficiently treated with the systemic antifungal therapy for
candidemia [54, 55]. Candida endophthalmitis extending
into the vitreous body commonly warrants surgical inter-
vention as well as intraocular antifungals.
Aspergillosis
Aspergillosis is the most common mould infection in hu-
mans, accounting for >85% of invasive mould disease [72].
Aspergillus is found in soil, decaying vegetation, food,
air, and the water supply [73]. Its ubiquitous spores reach
the respiratory tract by inhalation. In immunocompromised
hosts this results primarily in invasive pulmonary aspergil-
losis (IPA). Disseminated disease, the end-stage complica-
tion of IPA, involves predominantly the brain and kidneys.
Epidemiology
Worldwide there are 200 000 estimated annual cases of
invasive aspergillosis (IA) [3]. At present, approximately
50% of all IA are found in patients with haematological
malignancy, mostly acute myeloid leukaemia (AML), acute
lymphoblastic leukaemia (ALL), and recipients of allogen-
eic HSCT [15, 74]. Prolonged severe neutropenia (>10
days; <500 cell/mm3) as a result of chemotherapy is still
the single most important risk factor for IA. The introduc-
tion of mould-active prophylaxis with posaconazole after
2007 [13, 14] is likely to result in a reduction of IA in-
cidence in haemato-oncological patients (AML, HSCT): a
French prospective single-centre study described not only
Table 1: Prophylactic regimen with grade A1 and A2 recommendations for invasive candidiasis, aspergillosis, cryptococcal meningitis and Pneumocystis jirovecii
pneumonia (PCP).
Risk groups Aspergillosis Invasive candidiasis Cryptococcal meningitis PCP
Allogeneic HSCT
- Initial neutropenic phase Fluconazole TMP-SMX
- GVHD phase (start at 90–100
d)





Acute lymphoblastic leukaemia TMP-SMX







Solid organ transplantation No definitive recommendations
for prophylaxis
TMP-SMX
GVHD = graft-versus-host disease; HIV = human immunodeficiency virus; HSCT = haematopoietic stem cell transplant; SMX = sulfamethoxazole; TMP = trimethoprim
Data from references [66, 69, 149–154].
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a reduction in IA incidence in AML patients with posa-
conazole prophylaxis (7.3%) versus those without prophy-
laxis (15.5%) but also a decrease in mortality at day 100:
3.6% versus 10.6%, respectively [75]. An Austrian single-
centre study found unchanged rates of IFDs but no IA
in AML, ALL and HSCT patients after introducing posa-
conazole prophylaxis. This indicates a remarkable decrease
of IA, but also a high rate of breakthrough infections [76].
In keeping with this finding, the continued use of fluc-
onazole for prophylaxis in almost 50% of HSCT recipients
in a recent Swiss multicentre study resulted in almost 60%
IAs among all proven and probable IFDs [77]. Mortality
rates of haematological patients with IA in large clinical
treatment trials reached 29% at 3 months [14, 78].
In SOT recipients Aspergillus causes one out of five IFDs;
it is most commonly found in lung and heart-lung recipi-
ents. The 5-year cumulative incidence in all SOT recipients
of the TRANSNET study remained stable at 0.7%, with a
median time to diagnosis of 184 days [35, 79]. The domin-
ant risk factor in SOT recipients is not a depletion of pha-
gocytic neutrophils but their functional impairment by im-
munosuppressant drugs.
ICU patients represent the second largest at-risk population
for IA. Reported incidence rates are variable but generally
high (6.1 to 57/1 000 ICU admissions) [80, 81]. Underlying
malignancy in the ICU population is rare. Instead, patients
often present with exacerbations of chronic obstructive pul-
monary disease, which are treated with high-dose corticos-
teroids. Severe alcoholic liver cirrhosis is another more
recently reported risk factor in ICU patients [82, 83]. Crit-
ically ill patients with IA have remarkably high mortality
rates ranging from 46 to 80% [84, 85]. Only patients with
cerebral involvement, regardless of the underlying disease,
reach higher rates of 90% at 4 months [86].
IA has also been associated with concurrent viral respir-
atory infections due to H1N1 influenza, adenovirus [87],
and cytomegalovirus. Particularly in transplant recipients,
infection with cytomegalovirus exerts a powerful immun-
osuppressive effect [88, 89]. In addition, genetic factors
such as toll-like receptor-4 (TLR4) haplotypes [90] and
pentraxin 3 (PTX3) deficiency [91, 92] have been associ-
ated with an increased risk of IA. Ddespite a large number
of patients at-risk, only a minority eventually develop IA.
Clinical presentation
Like patients with invasive candidiasis, none of the at-risk
groups show specific clinical symptoms. In neutropenic pa-
tients fever unresponsive to broad-spectrum antibiotics is
often an early sign that should prompt further examination.
Rarely, a cough or chest pain with or without haemoptysis
– both signs of pulmonary infarction due to mould-induced
vascular obstruction – are reported [93]. On the other hand,
the critically ill ICU patient with IA is mostly mechanically
ventilated and may present with deteriorating lung func-
tion and refractory fever [86]. Progression to disseminated
disease is often an underdiagnosed complication, particu-
larly in patients with severe or advanced underlying disease
[94]. Seizures or other focal neurological signs may be a
late manifestation of cerebral dissemination [93]. Primary
extrapulmonary organ manifestation is rare [11].
Table 2: Therapeutic regiments with grade A1 recommendation for invasive candidiasis, aspergillosis, cryptococcal meningitis and Pneumocystis jirovecii pneumonia
(PCP).
Risk groups Aspergillosis Invasive candidiasis Cryptococcal meningitis PCP
Allogeneic
HSCT
Neutropenic patients: Caspofungin 70/
50 mg/d or anidulafungin 200/100 mg or
micafungin 100 mg or liposomal
amphotericin B 3 mg/kg/d. Fluconazole
may be used orally as step-down
therapy. Treatment continued for 14 days




Non-HIV / non-SOT: Induction –
Amphotericin B deoxycholate (0.7–1.0
mg/kg/d i.v.) or liposomal amphotericin B
(3–4 mg/kg/d i.v.) plus flucytosine (100
mg/kg/d p.o. in 4 divided doses) for at
least 4 weeks.
Consolidation: Fluconazole (400–800
mg/od p.o.) for 8 weeks. Maintenance:




SOT: Induction – Amphotericin B
deoxycholate (0.7–1.0 mg/kg/d i.v.) or
liposomal amphotericin B (3–4 mg/kg/d
i.v.) plus flucytosine (100 mg/kg/d p.o. in
4 divided doses) for at least 2 weeks.
Consolidation: Fluconazole (400–800
mg/od p.o.) for 8 weeks. Maintenance:
Fluconazole (200400 mg/d p.o.) for 6 to
12 months.
HIV negative: TMP-SMX: 15
mg TMP component/kg/day p.o.






All patients: Voriconazole (6
mg/kg i.v. BD for 1 d, followed
by 4 mg/kg i.v. BD; oral dosage
is 300 mg BD). Alternatively:
Liposomal amphotericin B (3–5
mg/kg/d i.v.).
Non-neutropenic patients:
Caspofungin 70/50 mg; anidulafungin
200/100 mg; micafungin 100 mg;
fluconazole may be used orally as step-
down therapy. Continued for 14 days
after first negative blood culture.
HIV positive: Induction – Amphotericin
B deoxycholate (0.7–1.0 mg/kg/d i.v.) or
liposomal amphotericin B (3–4 mg/kg/d
i.v.) plus flucytosine (100 mg/kg/d in 4
divided doses p.o.) for at least 2 weeks.
Consolidation: Fluconazole (400 mg/d
p.o.) for a minimum of 8 weeks.
Maintenance: Fluconazole (200 mg/d)
for secondary prophylaxis (min. 1 year) –
discontinuation not before CD4 count
>100 cell/μl.
HIV positive: TMP-SMX: 15 mg
TMP component/kg/day p.o. or
i.v. in 3 or 4 divided doses for 21
days.
BD = twice daily; i.v. = intravenously; HIV = human immunodeficiency virus; p.o. = orally; SMX = sulfamethoxazole; SOT = solid organ transplantation
Data from references [66, 69, 149, 151, 155–158]
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Diagnosis
The diagnosis of IA is challenging and requires a high level
of suspicion. The gold standard for proving invasive fungal
infection is histopathology or culture of a tissue sample,
which is rarely available on time because of the risks in-
volved in performing biopsies during pancytopenia [8].
Detection of galactomannan antigen (GM), a constituent of
the hyphal cell wall, in blood is currently the most widely
available albeit only moderately accurate noninvasive test
for invasive aspergillosis. It has a sensitivity of approxim-
ately 71% and a specificity of approximately 89% in high-
risk haematological patients [95]. In corticosteroid-treated
nonhaematology patients, GM detection in bronchoalveol-
ar lavage (BAL) fluid has higher sensitivity for IPA than
in blood [96]. Caution is warranted in patients on mould-
active prophylaxis as the sensitivity of the GM assay is
reduced [97], making it difficult to identify breakthrough
infection in haematological patients [98, 99]. Repeat sero-
logical tests of (1–3)-β-D-glucan may be used as adjunct in
the diagnosis of aspergillosis, although as a cell wall con-
stituent shared between Aspergillus spp., Candida spp., and
Pneumocystis jirovecii (but absent from Cryptococcus and
mucormycetes), it is nonspecific and a high rate of false-
positive results may render its interpretation difficult [100,
101]. Blood cultures are virtually always negative in IA [3]




Computed tomography images of invasive pulmonary aspergillosis.
a) Neutropenic patient, early stages: sharply demarcated nodes
and dense lesions surrounded by a ground-glass halo.
b) Rheumatology patient on corticosteroid treatment, early stages:
centrally cavitating dense lesions.
PCR may be a useful tool to diagnose aspergillosis. A re-
cent review reports mean sensitivity and specificity of a
single PCR test (plasma and serum) of 80.5% and 78.5%,
respectively, and of two consecutive PCRs of 58% and
96.2%, respectively [102]. The European Aspergillus PCR
initiative recently introduced a standardised PCR with bet-
ter sensitivity (95%) and specificity (83%) in plasma than
in serum [103]. The majority of IA cases (>90%) are
caused by A. fumigatus. A. flavus, A. terreus and A. niger.
Of therapeutic relevance is the identification of A. terreus
(see “Treatment” below).
Imaging studies often provide the first evidence of IA. In
neutropenic patients with fever not responding to antibiot-
ic treatment, a high-resolution computed tomography (CT)
scan of the thorax may reveal sharply demarcated nodes or
dense lesions surrounded by a ground-glass halo compat-
ible with, but not proof of, a fungal aetiology (fig. 1a). In
clinical practice, it may be difficult to dismiss the possibil-
ity of a fungal aetiology based on the radiomorphology of
a lesion [104, 105]. Whereas in neutropenic patients cent-
rally cavitating nodules (crescent sign) are a late sign of in-
vasive fungal infection appearing with the recovery from
neutropenia, cavitating pulmonary lesions may be an early
sign in, for example, rheumatology patients treated with
corticosteroids (fig. 1b). In contrast, in patients on steroid-
treatment due to exacerbated chronic lung disease, the CT
may only show non-specific pulmonary infiltrates [106].
Treatment
Mould-active prophylaxis is recommended for the duration
of the neutropenia associated with remission-induction
chemotherapy in high-risk patients with AML or myel-
odysplastic syndrome. Indications for prophylaxis are giv-
en in table 1. Starting treatment early is important in order
to reduce mortality. First-line treatment for IA is
voriconazole (table 2). Compared with amphotericin
deoxycholate it showed a survival benefit in haematologic-
al patients (71% vs 58%). Furthermore, voriconazole has
a more favourable adverse effect profile and, notably, no
nephrotoxicity [78]. However, because of extensive drug-
drug interactions and large inter- and intra-individual vari-
ation in serum levels, therapeutic drug monitoring is ad-
visable when using voriconazole. An equivalent alternative
may be liposomal amphotericin B, though no comparative
studies have been conducted. Although most Aspergillus
isolates exhibit good susceptibility to mould-active azoles
as well as amphotericin B, studies from the Netherlands,
Belgium and Germany have reported an increasing number
of azole-resistant clinical Aspergillus isolates [107–109].
A. terreus is constitutively resistant to amphotericin B [93].
It is recommended to continue treatment for invasive asper-
gillosis until all clinical signs and symptoms have resolved.
In haematological patients combination therapy with anid-
ulafungin and voriconazole showed no significant surviv-
al advantage over monotherapy with voriconazole [110].
Nevertheless, concomitant treatment with two antifungal
drugs of different classes may occasionally be used to ex-
tend the spectrum of activity when the pathogen is un-
known. Suspected coinfection with different fungal species
may be another reason for combining antifungal agents.
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Other measures such as reduction of iatrogenic immun-
osuppression should be considered [111].
Cryptococcosis
Epidemiology
With more than one million cases and about 650 000 deaths
annually, cryptococcosis is the most prevalent fatal fungal
disease worldwide [3, 112]. The most common disease
manifestation is cryptococcal meningitis presenting as an
opportunistic infection principally in the HIV positive with
CD4 cell counts below 100 cells/μl or the iatrogenically
immunosuppressed [113]. Cryptococcal meningitis is rare
in Europe but in sub-Saharan Africa annual incidence rates
range from 100/100 000 in high HIV prevalence settings
to 4 000/100 000 among the HIV positive [114, 115]. The
dominant species in this yeast genus is Cryptococcus neo-
formans, a ubiquitous environmental pathogen. Following
inhalation, cryptococcal yeasts are deposited in the lung
where they may cause life-long latent infection [116]. In a
USA study, 70% of 120 children older than five years were
seropositive for C. neoformans, indicating oligosympto-
matic infection early in life. Only in the immunosuppressed
patient, usually after adolescence, infection may reactivate
[117].
Globally, HIV remains the leading risk factor for CM, al-
though the widespread use of antiretroviral therapy has led
to a steady decline in HIV-associated CM [112, 113]. In
the developed world CM is now seen in approximately
2.8% of all SOT recipients, largely kidney transplant recip-
ients. Infection occurs mostly >18 months after transplant-
ation [118, 119]. Rarely, cryptococcosis is seen in appar-
ently immunocompetent hosts. A USA study found that, in
non-HIV and non-SOT patients, time to diagnosis was pro-
longed and outcome was worse compared with HIV posit-
ive individuals and SOT recipients [118]. Apparently im-
munocompetent patients are more likely to have pulmonary
disease and less likely to develop CM [120]. Disseminated
disease can reach any organ, but the lungs and the skin are
predominately affected [11].
Clinical presentation
Symptoms of CM are nonspecific. The clinical picture
ranges from minimal to severe symptoms with headache,
malaise, fever, visual disturbance, nausea and vomiting.
In contrast to bacterial meningitis, meningism is rare [11,
113]. Disease onset is variable, but tends to be more insidi-
ous in the immunocompetent than in those with advanced
HIV disease. Intracranial pressure is commonly raised and
seizures may occur in advanced disease. Pulmonary disease
produces nonspecific symptoms such as cough, fever and
malaise. Skin lesions, which predominately occur in im-
munocompromised patients, may present as pustules, pap-
ules, ulcers, cellulitis, superficial granulomas, or abscesses
[121, 122].
Diagnosis
Diagnosis of CM is established by positive fungal culture
or detection of cryptococcal antigen (CrAg) in cerebrospin-
al fluid. The CrAg test has a sensitivity and specificity of
>90% in both cerebrospinal fluid and serum [123]. In de-
veloping countries, a point-of-care urine dipstick test has
shown promising results [124]. The diagnosis of pulmon-
ary disease is based on a positive sputum culture in con-
junction with compatible imaging findings. A positive ser-
um CrAg in pulmonary disease may represent disseminated
disease [125]. Extracranial disease manifestation warrants
lumbar puncture to rule out possibly asymptomatic men-
ingitis [126, 127].
Treatment
The current treatment guidelines for CM are based on the
results of a randomised clinical trial showing superiority
of flucytosine over fluconazole in combination with am-
photericin B deoxycholate for induction therapy (table 2)
[127, 128]. Clinically, control of intracranial pressure is
pivotal: if the initial intracranial pressure exceeds 250 mm,
it should be decreased by 50% or at least to <200 mm.
Repeated daily drainage may be necessary [127]. For pul-
monary disease, recommended treatment regimens vary
with disease severity: severe disease is treated as CM
[129], moderate disease responds to oral fluconazole [11].
In CM patients with HIV, initiation of antiretroviral therapy
needs to be delayed for, generally, 5 weeks in order to avoid
early excess mortality [130]. In the early phase of antiretro-
viral therapy a potentially lethal immune-reconstitution in-
flammatory syndrome occurs in approximately 14–30% of
individuals successfully treated for cryptococcosis [131].
Pneumocystis jirovecii pneumonia
Epidemiology
Traditionally considered a protozoan, Pneumocystis has
been shown to belong to the family of fungi. An important
reservoir of this opportunistic organism is children, most of
whom are infected early in life and may transmit the organ-
ism from person to person via the airborne route [11, 132].
It is currently unclear whether clinical disease results from
recent reinfection or from reactivation of latent infection in
the naturally colonised host [133]. It is estimated that ap-
proximately 400 000 individuals are affected by Pneumo-
cystis jirovecii pneumonia (PCP) every year – as many as
by C. albicans [3]. In the Western world, PCP used to be
the most common opportunistic infection in HIV-positive
individuals [134]. With the introduction of antiretroviral
therapy, the incidence of PCP has significantly decreased.
Today, the principal risk group comprises patients who are
iatrogenically immunocompromised because of either ma-
lignancy, transplantation or rheumatological disease. In a
recent European study PCP was the second most common
invasive fungal infection in a mixed HIV-positive and -neg-
ative population, with an incidence rate of 1.5/100 000 and
a fatality rate of 9.5% [135]. Counterintuitively, mortality
rates in HIV-negative patients were higher (30–60%) than
in HIV-positive individuals (10–20%) [135–137].
Clinical presentation
The clinical course depends on the underlying disease.
Generally, in HIV-positive patients the onset of disease is
insidious and prolonged, whereas in non-HIV patients dis-
Review article: Current opinion Swiss Med Wkly. 2016;146:w14281
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 6 of 12
ease progression tends to be more fulminant – possibly
explaining the increased mortality in this group. Clinical
symptoms are nonspecific including low-grade fever, dry
cough and progressive dyspnoea. Lung auscultation is
commonly normal [138].
Diagnosis
The diagnosis is confirmed by the detection of the fungal
organisms obtained via BAL or induced sputum using
fluorescence microscopy in conjunction with a radiological
image [139, 140]. Radiological signs include bilateral peri-
hilar interstitial infiltrates [141]. In the early disease stage
a chest x-ray may be normal. High-resolution CT is more
sensitive, revealing perihilar ground-glass attenuation or
cystic lesions [142]. In patients who cannot tolerate bron-
choscopy, the serum (1–3)-β-D-glucan is a good adjunct
marker with a test sensitivity of 96% and specificity of
87% [143]. The diagnostic yield of any specimen from HIV
patients is higher than from HIV-negative patients [144].
Several trials have shown good sensitivities and specificit-
ies of real-time PCR [145, 146]. However, so far there is
no standardised method and the additional problem of dis-
tinguishing between (frequent) colonisation and infection
is unresolved.
Treatment
Prophylaxis should be given to all those at risk (table 1).
Owing to lack of ergosterol in the plasma membrane,
Pneumocystis jirovecii is insensitive to polyenes and azoles
[11]. Current treatment regimens (table 2) are primarily
based on trimethoprim/sulfamethoxazole. In HIV patients
with an initial PO2 <70 mm Hg, the additional adminis-
tration of corticosteroids has resulted in improved surviv-
al [147]. The treatment duration is only well established in
HIV-positive patients and lasts for 3 weeks, while non-HIV
patients are commonly given a 14-day course. In the case
of intolerance to trimethoprim/sulfamethoxazole, clinda-
mycin plus primaquine, atovaquone or trimethoprim/
dapsone are alternative regimens [148].
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Figures (large format)
Figure 1
Computed tomography images of invasive pulmonary aspergillosis.
a) Neutropenic patient, early stages: sharply demarcated nodes and dense lesions surrounded by a ground-glass halo.
b) Rheumatology patient on corticosteroid treatment, early stages: centrally cavitating dense lesions.
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